The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances.

Heng F, Magaret CA, Rouphael NG, Branche AR, Fong Y, Carpp LN, Yu C, Chen S, Zhang B, Diemert DJ, Falsey AR, Graciaa DS, Baden LR, Frey SE, Whitaker JA, Little SJ, Kamidani S, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Mu J, Makowski M, Makhene MK, Nayak SU, Simon V, van Bakel H, Roberts PC, Gilbert PB, Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team

Open source

DOI
10.1016/j.vaccine.2026.128348
Published
2026 Mar 19
Container
Vaccine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.vaccine.2026.128348,
  title = {The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances.},
  author = {Heng F and Magaret CA and Rouphael NG and Branche AR and Fong Y and Carpp LN and Yu C and Chen S and Zhang B and Diemert DJ and Falsey AR and Graciaa DS and Baden LR and Frey SE and Whitaker JA and Little SJ and Kamidani S and Walter EB and Novak RM and Rupp R and Jackson LA and Babu TM and Kottkamp AC and Luetkemeyer AF and Immergluck LC and Presti RM and Bäcker M and Winokur PL and Mahgoub SM and Goepfert PA and Fusco DN and Atmar RL and Posavad CM and Mu J and Makowski M and Makhene MK and Nayak SU and Simon V and van Bakel H and Roberts PC and Gilbert PB and Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team},
  year = {2026},
  journal = {Vaccine},
  doi = {10.1016/j.vaccine.2026.128348},
  url = {https://doi.org/10.1016/j.vaccine.2026.128348}
}

RIS

TY  - JOUR
TI  - The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances.
AU  - Heng F
AU  - Magaret CA
AU  - Rouphael NG
AU  - Branche AR
AU  - Fong Y
AU  - Carpp LN
AU  - Yu C
AU  - Chen S
AU  - Zhang B
AU  - Diemert DJ
AU  - Falsey AR
AU  - Graciaa DS
AU  - Baden LR
AU  - Frey SE
AU  - Whitaker JA
AU  - Little SJ
AU  - Kamidani S
AU  - Walter EB
AU  - Novak RM
AU  - Rupp R
AU  - Jackson LA
AU  - Babu TM
AU  - Kottkamp AC
AU  - Luetkemeyer AF
AU  - Immergluck LC
AU  - Presti RM
AU  - Bäcker M
AU  - Winokur PL
AU  - Mahgoub SM
AU  - Goepfert PA
AU  - Fusco DN
AU  - Atmar RL
AU  - Posavad CM
AU  - Mu J
AU  - Makowski M
AU  - Makhene MK
AU  - Nayak SU
AU  - Simon V
AU  - van Bakel H
AU  - Roberts PC
AU  - Gilbert PB
AU  - Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team
PY  - 2026
JO  - Vaccine
DO  - 10.1016/j.vaccine.2026.128348
UR  - https://doi.org/10.1016/j.vaccine.2026.128348
ER  -

APA

F, H., CA, M., NG, R., AR, B., Y, F., LN, C., C, Y., S, C., B, Z., DJ, D., AR, F., DS, G., LR, B., SE, F., JA, W., SJ, L., S, K., EB, W., RM, N., R, R., LA, J., TM, B., AC, K., AF, L., LC, I., RM, P., M, B., PL, W., SM, M., PA, G., DN, F., RL, A., CM, P., J, M., M, M., MK, M., SU, N., V, S., H, V. B., PC, R., PB, G., & Team, C. V. I. L. T. (. S. (2026). The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances.. Vaccine. https://doi.org/10.1016/j.vaccine.2026.128348

Source records